☰

Deanna A. Mele, Ph.D. - Publications

Affiliations: 
2009 Cellular & Molecular Physiology Sackler School of Graduate Biomedical Sciences (Tufts University) 
Area:
Cell Biology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

14 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Revenko A, Carnevalli LS, Sinclair C, Johnson B, Peter A, Taylor M, Hettrick L, Chapman M, Klein S, Solanki A, Gattis D, Watt A, Hughes AM, Magiera L, Kar G, ... ... Mele DA, et al. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. Journal For Immunotherapy of Cancer. 10. PMID 35387780 DOI: 10.1136/jitc-2021-003892  0.324
2020 Borodovsky A, Barbon CM, Wang Y, Ye M, Prickett L, Chandra D, Shaw J, Deng N, Sachsenmeier K, Clarke JD, Linghu B, Brown GA, Brown J, Congreve M, Cheng RK, ... ... Mele DA, et al. Small molecule AZD4635 inhibitor of AR signaling rescues immune cell function including CD103 dendritic cells enhancing anti-tumor immunity. Journal For Immunotherapy of Cancer. 8. PMID 32727810 DOI: 10.1136/Jitc-2019-000417  0.382
2020 Chandra D, Barbon CM, Borodovsky A, Wang Y, Ye M, Prickett L, Sachsenmeier K, Shao W, Barrett C, Fawell S, Mele DA, Schuller A. Abstract A87: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression in tumor microenvironment and enhances antitumor immunity partly by enhancing CD103+ dendritic cells Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-A87  0.43
2020 Grimster N, Drew L, Fawell S, Mele DA, Bommakanti G, Shen M, Xu K, Song K, Ziegler R, Kettle J, Mfuh A, Sheilds J. Abstract A56: Releasing the brake on T-cell activation through inhibition of HPK1 Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-A56  0.509
2019 O' Donovan DH, Mao Y, Mele DA. The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy. Current Medicinal Chemistry. PMID 31250749 DOI: 10.2174/0929867326666190620103105  0.327
2019 Barbon CM, Borodovsky A, Wang Y, Prickett L, Sachsenmeier K, Schuller A, Shao W, Barrett C, Fawell S, Mele DA. Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-192  0.439
2018 Langdon S, Hughes A, Taylor MA, Kuczynski EA, Mele DA, Delpuech O, Jarvis L, Staniszewska A, Cosulich S, Carnevalli LS, Sinclair C. Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology. 7: e1458810. PMID 30221055 DOI: 10.1080/2162402X.2018.1458810  0.359
2016 Ghosh S, Taylor A, Chin M, Huang HR, Conery AR, Mertz JA, Salmeron A, Dakle PJ, Mele D, Cote A, Jayaram H, Setser JW, Poy F, Hatzivassiliou G, DeAlmeida-Nagata D, et al. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. The Journal of Biological Chemistry. PMID 27056325 DOI: 10.1074/Jbc.M115.708560  0.399
2013 Mele DA, Salmeron A, Ghosh S, Huang HR, Bryant BM, Lora JM. BET bromodomain inhibition suppresses TH17-mediated pathology. The Journal of Experimental Medicine. 210: 2181-90. PMID 24101376 DOI: 10.1084/Jem.20130376  0.414
2011 Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of the United States of America. 108: 16669-74. PMID 21949397 DOI: 10.1073/Pnas.1108190108  0.408
2011 Mele DA, Sampson JF, Huber BT. Th17 differentiation is the default program for DPP2-deficient T-cell differentiation. European Journal of Immunology. 41: 1583-93. PMID 21469121 DOI: 10.1002/Eji.201041157  0.552
2009 Danilova OV, Tai AK, Mele DA, Beinborn M, Leiter AB, Greenberg AS, Perfield JW, Defuria J, Singru PS, Lechan RM, Huber BT. Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesity. Endocrinology. 150: 5240-8. PMID 19819973 DOI: 10.1210/En.2009-0386  0.458
2009 Mele DA, Bista P, Baez DV, Huber BT. Dipeptidyl peptidase 2 is an essential survival factor in the regulation of cell quiescence. Cell Cycle (Georgetown, Tex.). 8: 2425-34. PMID 19556882 DOI: 10.4161/Cc.8.15.9144  0.525
2008 Bista P, Mele DA, Baez DV, Huber BT. Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1. Molecular Immunology. 45: 3618-23. PMID 18555530 DOI: 10.1016/J.Molimm.2008.05.001  0.547
Show low-probability matches.